Danaher

Danaher reports a Q3 revenue increase of 8.5% to $6.6 billion and net income of $1.2 billion. Adjusted earnings per share were $2.11, beating the $1.91 expectation; operating cash flow was $1.9 billion and free cash flow rose 19% to $1.63 billion. As a result, Danaher raises its full-year guidance for adjusted EPS to $8.57–$8.62; the stock gains and also lifts Sartorius' preferred share higher. » Mais em deraktionaer.de

Aristotle Value Equity Fund flagged Danaher as a core holding, citing disciplined capital allocation, the Danaher Business System, strong free cash flow and a high share of recurring consumables revenue. The letter notes Danaher’s transformation into a focused healthcare company through spinoffs and acquisitions such as Pall, Cepheid and Cytiva, which bolstered predictable workflow-based revenues. Danaher shares gained about 10.6% over one month and traded near $215 with a market cap around $155.6 billion; the fund said its overall underperformance in Q2 was due to limited exposure to the AI infrastructure rally. » Mais em finance.yahoo.com

Danaher reported improving life‑sciences trends with its Life Sciences unit delivering the strongest performance in years and bioprocessing orders growing mid‑teens, suggesting underlying demand for consumables and equipment is solid. Management said just over $100 million of revenue shifted into next year, indicating delayed rather than lost customer projects, but cut the upper end of its full‑year core revenue growth outlook to 4% due to weakness in biotechnology and respiratory testing. The company’s recovery appears broadening but remains uneven across end markets, leaving investors to weigh near‑term cyclical improvements against lingering pockets of weakness. » Mais em finance.yahoo.com

Danaher's quarterly report disappointed in diagnostics and bioprocessing, and the stock fell by about 14 percent. Weak operating performance and timing delays on customer projects in bioprocessing also weighed on Sartorius's stock, which lost up to 12 percent. Analysts see short-term disappointments and a muted outlook for Q3 but consider the long-term prospects intact and view the price weakness partly as a buying opportunity, with revenue growth expected to accelerate from 2027. » Mais em de.investing.com

Analysts name Danaher among the best non-tech stocks to buy while brokers hold mixed stances. Masimo announced FDA 510(k) clearance for an opioid‑induced respiratory depression detection feature integrated into its Radius VSM wearable monitor, a development tied to Danaher’s diagnostics exposure. Wolfe Research downgraded Danaher to Peer Perform citing uncertainty over the Masimo transaction, while Piper Sandler initiated coverage awaiting new growth catalysts. Danaher continues to operate across Diagnostics, Biotechnology, Life Sciences and Environmental and Applied Solutions. » Mais em finance.yahoo.com